- Home
- RNP vs COLL Comparison
RNP vs COLL Comparison
Compare RNP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- COLL
- Stock Information
- Founded
- RNP 2003
- COLL 2002
- Country
- RNP United States
- COLL United States
- Employees
- RNP N/A
- COLL N/A
- Industry
- RNP Investment Managers
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- RNP Finance
- COLL Health Care
- Exchange
- RNP Nasdaq
- COLL Nasdaq
- Market Cap
- RNP 1.1B
- COLL 958.8M
- IPO Year
- RNP N/A
- COLL 2015
- Fundamental
- Price
- RNP $22.39
- COLL $36.01
- Analyst Decision
- RNP
- COLL Strong Buy
- Analyst Count
- RNP 0
- COLL 4
- Target Price
- RNP N/A
- COLL $44.25
- AVG Volume (30 Days)
- RNP 117.6K
- COLL 433.7K
- Earning Date
- RNP 01-01-0001
- COLL 11-06-2025
- Dividend Yield
- RNP 7.94%
- COLL N/A
- EPS Growth
- RNP N/A
- COLL N/A
- EPS
- RNP N/A
- COLL 1.06
- Revenue
- RNP N/A
- COLL $707,007,000.00
- Revenue This Year
- RNP N/A
- COLL $22.23
- Revenue Next Year
- RNP N/A
- COLL $2.78
- P/E Ratio
- RNP N/A
- COLL $35.25
- Revenue Growth
- RNP N/A
- COLL 22.61
- 52 Week Low
- RNP $15.52
- COLL $23.23
- 52 Week High
- RNP $21.27
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- RNP 54.04
- COLL 45.16
- Support Level
- RNP $22.08
- COLL $37.10
- Resistance Level
- RNP $22.44
- COLL $39.12
- Average True Range (ATR)
- RNP 0.24
- COLL 1.12
- MACD
- RNP 0.02
- COLL -0.49
- Stochastic Oscillator
- RNP 74.91
- COLL 2.98
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.